Smith & Nephew (SN.L) Stock Price
Smith & Nephew Price
Over the last 19 years Smith & Nephew grew revenue by 4.4% annually, reaching 6.29 B USD. Earnings per share have declined at 0.4% per year over the last 19 years. For Smith & Nephew, the net margin of 10.1% is broadly stable versus 10.1% a few years ago. At today's price the dividend yield works out to roughly 1.84%. The payout ratio is around 39% of earnings. The dividend has grown at 5.0% per year over the past 19 years.
Smith & Nephew stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Smith & Nephew business model & stock analysis
Frequently asked questions about Smith & Nephew
The business model of Smith & Nephew PLC is focused on providing innovative medical devices and advanced technology solutions to improve patient outcomes and enhance healthcare efficiency. As a leading global medical technology company, Smith & Nephew specializes in the areas of orthopedics, sports medicine, and advanced wound management. Combining research, development, manufacturing, and marketing capabilities, the company aims to address unmet medical needs and deliver high-quality products and services to healthcare professionals and patients worldwide. Smith & Nephew PLC strives to continuously innovate and collaborate with healthcare stakeholders to make a meaningful difference in the field of medical technology.
Smith & Nephew PLC is primarily active in the medical device industry.
The main competitors of Smith & Nephew PLC in the market include Medtronic PLC, Stryker Corporation, and Johnson & Johnson.
Smith & Nephew PLC is a renowned medical technology company with a rich history and background. Founded in 1856, the company has evolved into a global leader in advanced healthcare solutions. Smith & Nephew specializes in developing innovative products and medical devices across various segments, including orthopedics, sports medicine, and advanced wound management. With a strong commitment to improving patient outcomes, the company's cutting-edge technology and dedication to research have led to significant advancements in surgical procedures and wound care management. Smith & Nephew PLC's long-standing history of excellence and continuous innovation position it as a trusted name in the medical industry.
Smith & Nephew PLC, a leading medical technology company, has achieved several significant milestones throughout its history. Since its inception, the company has been at the forefront of innovation, revolutionizing the healthcare industry. Smith & Nephew expanded its global presence and experienced substantial growth, establishing a strong reputation for excellence. The company's achievements include the development of groundbreaking products and solutions, successful acquisitions and partnerships, and recognition for its commitment to patient care. Smith & Nephew PLC continues to make remarkable strides, driving advancements in medical technology and making a positive impact in the lives of patients worldwide.
Smith & Nephew PLC is primarily present in various countries and regions worldwide. The company has a global presence and operates in key markets such as the United States, the United Kingdom, Europe, Asia Pacific, and the Middle East. It has a wide reach and serves patients and healthcare professionals in many countries, including the United States, Canada, Germany, France, China, Japan, Australia, and the United Arab Emirates. With its extensive international presence, Smith & Nephew PLC is able to provide innovative medical solutions and services to customers across different regions and deliver quality healthcare products to a diverse range of patients worldwide.
Smith & Nephew PLC represents a strong commitment to providing innovative medical solutions and advanced healthcare technology. The company values include a focus on patient-centered care, continuous improvement, integrity, and collaboration. Smith & Nephew is dedicated to improving the quality of life for patients around the world through their range of products and services. They prioritize delivering superior outcomes for patients, healthcare professionals, and stakeholders. The corporate philosophy of Smith & Nephew revolves around driving sustainable growth, embracing diversity and inclusion, and maintaining their position as a global leader in medical technology.
24 analysts currently rate the Smith & Nephew stock: 13 recommend buying, 10 holding and 1 selling. For 2026, analysts expect Smith & Nephew to generate revenue of 6.45 B USD and earnings per share of 1.09 USD.
Converted at the current exchange rate, the Smith & Nephew share trades at 14.02 EUR (15.64 USD).
The Smith & Nephew share (SN.L) is listed on 7 stock exchanges, including: London (SN.L), SIX (Zürich) (NPW1.SW), Frankfurt (NPW1.F), München (NPW1.MU), Düsseldorf (NPW1.DU).
Smith & Nephew PLC is a global company specializing in medical technology. The company offers a wide range of products and solutions for orthopedics, sports medicine, biologics, and wound care. The orthopedics division of Smith & Nephew manufactures innovative products for the treatment of joint problems. This includes implants for hip, knee, shoulder, elbow, and hand joints, which are developed and produced by the company itself. In addition, Smith & Nephew also offers instruments that are used during surgeries. The sports medicine division of Smith & Nephew specializes in developing solutions for the treatment of sports injuries. This includes arthroscopy cameras, products for repairing synovial tissue, and other instruments that allow doctors to diagnose and treat injuries. The biologics division of Smith & Nephew produces products that focus on tissue regeneration. This includes biodegradable polymers, growth factors, and synthetic bone substitutes. These products can help support the natural healing of bones and tissues and can be used in various medical fields. The wound care division of Smith & Nephew produces a wide range of products that can be used for wound care in patients. This includes dressings, wound dressings, and antiseptics. An important factor of Smith & Nephew's business model is the company's global expansion. The company is present in over 100 countries and continuously works to expand its presence on a global level. This allows the company to sell its products on a broader scale and increase its market share. Another important factor of Smith & Nephew's business model is its focus on research and development. The company invests a significant portion of its operating profit in research and development to develop innovative products and improve existing solutions. This allows the company to offer cutting-edge technologies to its customers worldwide and increase its competitiveness in the market. Overall, Smith & Nephew's business model is focused on delivering innovative solutions for the medical care of patients. The company relies on a wide range of products, international expansion, and high investments in research and development to offer our customers worldwide high-quality products and services.
The expected revenue of Smith & Nephew is 6.45 B USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Smith & Nephew is 954.26 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Smith & Nephew is currently 14.31. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Smith & Nephew stock.
The price-to-sales ratio (P/S) of Smith & Nephew is currently 2.12. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Smith & Nephew stock.
The Eulerpool Quality Score for Smith & Nephew is 5/10.
The ISIN of Smith & Nephew is GB0009223206. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Smith & Nephew is 502816. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Smith & Nephew is SN.L. The ticker symbol is used to trade Smith & Nephew shares on the stock exchange.
Smith & Nephew stock
Smith & Nephew Peer Group
Smith & Nephew Ticker
Smith & Nephew FIGI
All fundamentals and in-depth analysis of Smith & Nephew
Our stock analysis for Smith & Nephew stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Smith & Nephew. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.